Advertisement

Organisation › Details
Novartis AG (NYSE: NVS)
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. *
![]() |
Start | 1996-12-20 merged |
Group | Novartis (Group) | |
![]() |
Industry | LIFE SCIENCES |
![]() |
Person | Narasimhan, Vasant (Vas) (Novartis 201408– Global Head Developm Novartis Pharma before Global Head Developm Vaccines |
Person 2 | Reinhardt, Jörg (Novartis 201308– Board Chairman before Bayer 201008– CEO Bayer HealthCare AG before Novartis COO) | |
![]() |
Region | Basel BS |
Country | Switzerland | |
City | 4002 Basel BS | |
Tel | 41 61 324 8000 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | J: more than 100,0 (2018-12-31) |
Currency | USD | |
Annual sales | 47,498,000,000 (sales, net, continued operations, consolidated (2019) 2019-12-31) | |
Profit | 7,147,000,000 (2019-12-31) | |
Cash | 11,112,000,000 (2019-12-31) | |
* Document for �About Section�: | ||
Record changed: 2022-04-05 |
Advertisement
![Picture [iito] Fighting Customers 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-fighting-customers.jpg)
More documents for Novartis (Group)
- [1] Novartis AG. (4/4/22). "Press Release (Ad hoc): Novartis Announces New Organizational Structure to Accelerate Growth, Strengthen Pipeline and Increase Productivity". Basel....
- [2] Epsilogen Ltd.. (3/2/22). "Press Release: Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing". London....
- [3] Poseida Therapeutics, Inc.. (2/22/22). "Press Release: Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy". San Diego, CA....
- [4] Rentschler Biopharma SE. (2/3/22). "Press Release: Rentschler Biopharma further Strengthens Company Leadership Team". Laupheim....
- [5] Merck KGaA. (1/13/22). "Press Release: Merck Announces New Appointments in Global R&D and Strategy Leadership for Healthcare Business Sector". Darmstadt....
- [6] Molecular Partners AG. (1/10/22). "Press Release: Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19". Zürich-Schlieren & Concord, MA....
- [7] Novartis AG. (1/6/22). "Press Release: Novartis Announces Collaboration with Alnylam to Explore Targeted Therapy to Restore Liver Function". Basel....
- [8] Novartis AG. (12/22/21). "Press Release: Novartis to Acquire Gyroscope Therapeutics, Adding a One-time Gene Therapy that Could Transform Care for Geographic Atrophy, a Leading Cause of Blindness". Basel....
- [9] Novartis AG. (12/20/21). "Press Release: Novartis Strengthens Immunotherapy Pipeline with Option, Collaboration and License Agreement with BeiGene for TIGIT inhibitor Ociperlimab". Basel....
- [10] Molecular Partners AG. (12/14/21). "Press Release: Molecular Partners Announces Collaboration with Novartis to Develop DARPin-conjugated Radioligand Therapeutic Candidates for Oncology". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top